RBC Capital Markets adjusted their outlook on Morgan Stanley (NYSE:MS) shares, raising the price target from $122.00 to ...
RBC Capital Markets adjusted its stance on Intra-Cellular Therapies shares, downgrading the biopharmaceutical company from Outperform to Sector Perform. The firm, however, raised its price target on ...
In a report released today, Adam Jonas from Morgan Stanley maintained a Buy rating on Ferrari (RACE – Research Report), with a price target of ...
RBC Capital analyst Luca Issi maintained a Buy rating on RegenXBio (RGNX – Research Report) today and set a price target of $30.00. The ...
RBC Capital Markets analyst Maurice Choy identifies relative “safer havens” in the yield-heavy energy infrastructure sector, ...
Morgan Stanley's profit more than doubled in the fourth quarter, fueled by a wave of dealmaking and stock sales that drove ...
Inc. is well-positioned to challenge Carl Sagan's 1995 prophecy of a declining U.S. manufacturing sector, as the integration ...
Daniel Fannon; Analyst; Jefferies & Company Inc. Gerard Cassidy; Analyst; RBC Capital Markets ...
https://www.tipranks.com/news/the-fly/wintrust-financial-price-target-raised-to-152-from-148-at-rbc-capital Morgan Stanley analyst Jeffrey Adelson raised the firm’s ...
Research analysts at BMO Capital Markets began coverage on shares of Toast (NYSE:TOST – Get Free Report) in a report released on Monday,Benzinga reports. The brokerage set an “outperform” rating and a ...
"Prices have moved up nearly 16% since Thursday with no 'normal' reasons that could justify this price action," Tyler Broda, an RBC Capital Markets analyst, said in a February 1 research note.
This strong showing in capital markets activities positions Morgan Stanley favorably for potential future growth in these areas. Strategic Focus on Wealth Management and Capital Return Morgan ...